Search results for "PROSTATE CANCER"

showing 10 items of 413 documents

Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zole…

2008

Abstract Background In addition to other treatments, patients with prostate cancer (pCA) and bone metastasis receive bisphosphonates. Since 2003, a previously unknown side-effect of bisphosphonates—bisphosphonate-associated osteonecrosis of the jaws (BP-ONJ)—has been described, and frequency has since increased. An exact incidence is still unknown. Objectives The aim of this study was to assess the incidence and additional factors in the development of BP-ONJ. Design, setting, and participants From July 2006 to October 2007, patients with advanced pCA and osseous metastasis receiving bisphosphonate therapy in the Department of Urology or Haematology and Oncology at the Johannes-Gutenberg-Un…

Malemedicine.medical_specialtyUrologymedicine.medical_treatmentBone NeoplasmsZoledronic AcidProstate cancerRisk FactorsInternal medicineGermanymedicinePrevalenceHumansProspective cohort studyAgedRetrospective StudiesBisphosphonate-associated osteonecrosis of the jawBone Density Conservation AgentsDiphosphonatesbusiness.industryIncidence (epidemiology)ImidazolesOsteonecrosisBone metastasisProstatic NeoplasmsRetrospective cohort studyBisphosphonateMiddle Agedmedicine.diseasePrognosisSurgeryZoledronic acidCross-Sectional StudiesInjections IntravenousbusinessJaw Diseasesmedicine.drugFollow-Up StudiesEuropean urology
researchProduct

Salvage Therapy With Oral Metronomic Cyclophosphamide and Methotrexate for Castration refractory Metastatic Adenocarcinoma of the Prostate Resistant …

2011

Objective To investigate the activity and toxicity of metronomic chemotherapy with low-dose oral cyclophosphamide (CTX) and methotrexate (MTX) in patients with metastatic CRPC that progresses after docetaxel. Patients with castration-resistant prostate cancer (CRPC) that progresses after docetaxel may benefit from receiving further chemotherapy. Methods Patients were treated with CTX 50 mg/d p.o. plus MTX 2.4 mg p.o. twice per week without rest periods. All patients received simultaneous luteinizing hormone-releasing hormone analogue. Prostate-specific antigen (PSA) response was defined as a 50% reduction on 2 evaluations at least 4 weeks apart. Objective response was measured according to …

Malemedicine.medical_specialtyUrologymedicine.medical_treatmentSalvage therapyPhases of clinical researchAdministration OralAntineoplastic AgentsDocetaxelAdenocarcinomaGastroenterologyCyclophosphamide docetaxel methotrexate metronomic chemotherapy prostate carcinomaSettore MED/24 - UrologiaProstate cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansTreatment FailureCyclophosphamideSalvage TherapyChemotherapyLeukopeniabusiness.industryProstatic Neoplasmsmedicine.diseaseMetronomic ChemotherapySurgeryMethotrexateDocetaxelTolerabilityAdministration MetronomicTaxoidsmedicine.symptombusinessmedicine.drug
researchProduct

Primary Radical Prostatectomy or Ablative Radiotherapy as Protective Factors for Patients With mCRPC Treated With Radium-223 Dichloride: An Italian M…

2020

Abstract Background We investigated, in a real-life setting, the prognostic relevance of previous primary treatment (radical prostatectomy [RP] or external beam radiotherapy [EBRT]) on overall survival for patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (223Ra). Materials and Methods In the present multicenter retrospective study, we enrolled 275 consecutive patients. The demographic and clinical data and mCRPC characteristics were recorded and evaluated at baseline and at the end of treatment or progression. 223Ra was administered according to the current label authorization until disease progression or unacceptable toxicity. We divided the who…

Malemedicine.medical_specialtyUrologymedicine.medical_treatmentoverall survivalBrachytherapy030232 urology & nephrologyUrology223-ra03 medical and health sciencesProstate cancer0302 clinical medicineAblative casemedicineHumansExternal beam radiotherapyradiotherapyAgedRetrospective StudiesAged 80 and overProstatectomyRadioisotopesbusiness.industryProstatectomyRetrospective cohort studymCRPCMiddle AgedProtective Factorsmedicine.diseasePrognosisCombined Modality TherapyRadiation therapySurvival RateProstatic Neoplasms Castration-ResistantOncologyMulticenter study223-ra; mCRPC; prostatectomy; radiotherapy; overall survivalItaly030220 oncology & carcinogenesisCohortDisease ProgressionbusinessSettore SECS-S/01Follow-Up StudiesRadium
researchProduct

Basal growth hormone concentrations in blood and the risk for prostate cancer: A case-control study

2005

OBJECTIVE To assess the relationship between basal serum growth hormone (GH) levels and prostate cancer risk. METHODS We conducted a population-based case-control study; cases included 68 men, aged 45–85 years, diagnosed with incident, primary, histologically confirmed, and clinically apparent (stage B and higher) prostate cancer. Controls included 240 men, frequency matched on age and residential area. Age, race, BMI, waist circumference, history of enlarged prostate, education, and current smoking status, were all considered as possible confounders. RESULTS We found a statistically significant trend of decreasing prostate cancer risk across increasing GH quintiles, in both crude (OR: 0.31…

Malemedicine.medical_specialtyWaistUrologyPopulationGastroenterologyProstate cancerBasal (phylogenetics)Risk FactorsInternal medicineBiomarkers TumormedicineHumansInsulin-Like Growth Factor IRisk factoreducationAgedAged 80 and overeducation.field_of_studybusiness.industryConfoundingCase-control studyProstatic NeoplasmsMiddle Agedmedicine.diseaseGrowth hormone secretionEndocrinologyOncologyCase-Control StudiesGrowth HormonebusinessThe Prostate
researchProduct

A Survey of Prostate Segmentation Methodologies in Ultrasound, Magnetic Resonance and Computed Tomography Images

2012

Prostate segmentation is a challenging task, and the challenges significantly differ from one imaging modality to another. Low contrast, speckle, micro-calcifications and imaging artifacts like shadow poses serious challenges to accurate prostate segmentation in transrectal ultrasound (TRUS) images. However in magnetic resonance (MR) images, superior soft tissue contrast highlights large variability in shape, size and texture information inside the prostate. In contrast poor soft tissue contrast between prostate and surrounding tissues in computed tomography (CT) images pose a challenge in accurate prostate segmentation. This article reviews the methods developed for prostate gland segmenta…

Malemedicine.medical_specialty[INFO.INFO-IM] Computer Science [cs]/Medical ImagingHealth Informatics02 engineering and technology030218 nuclear medicine & medical imagingProstate -- Cancer-- DiagnosisPròstata -- Càncer -- Diagnòstic03 medical and health sciencesProstate cancerSpeckle pattern0302 clinical medicineProstateProstate -- Cancer -- Imaging0202 electrical engineering electronic engineering information engineering[INFO.INFO-IM]Computer Science [cs]/Medical ImagingMedicineHumansComputer visionSegmentationPròstata -- Càncer -- ImatgesUltrasonographyModalitiesModality (human–computer interaction)medicine.diagnostic_test[ INFO.INFO-IM ] Computer Science [cs]/Medical Imagingbusiness.industryUltrasoundProstateMagnetic resonance imagingmedicine.diseaseMagnetic Resonance Imaging3. Good healthComputer Science Applicationsmedicine.anatomical_structureImatgeria mèdica020201 artificial intelligence & image processingArtificial intelligenceRadiologybusinessTomography X-Ray ComputedSoftwareAlgorithmsImaging systems in medicine
researchProduct

Urinary and sexual outcomes in long-term (5+ years) prostate cancer disease free survivors after radical prostatectomy.

2009

Abstract Background After long term disease free follow up (FUp) patients reconsider quality of life (QOL) outcomes. Aim of this study is assess QoL in prostate cancer patients who are disease-free at least 5 years after radical prostatectomy (RP). Methods 367 patients treated with RP for clinically localized pCa, without biochemical failure (PSA ≤ 0.2 ng/mL) at the follow up ≥ 5 years were recruited. Urinary (UF) and Sexual Function (SF), Urinary (UB) and Sexual Bother (SB) were assessed by using UCLA-PCI questionnaire. UF, UB, SF and SB were analyzed according to: treatment timing (age at time of RP, FUp duration, age at time of FUp), tumor characteristics (preoperative PSA, TNM stage, pa…

Malemedicine.medical_specialtymedia_common.quotation_subjectUrinary systemmedicine.medical_treatmentSexual BehaviorUrologyUrinationUrinary incontinencelcsh:Computer applications to medicine. Medical informaticsUrinationProstate cancerQuality of lifeMedicineHumansSurvivorsmedia_commonAgedAged 80 and overProstatectomybusiness.industryProstatectomyResearchPublic Health Environmental and Occupational HealthProstatic NeoplasmsGeneral MedicineMiddle Agedmedicine.diseaseErectile dysfunctionProstatic NeoplasmQuality of Lifelcsh:R858-859.7Survivormedicine.symptomSexual functionbusinessHumanHealth and quality of life outcomes
researchProduct

PI-RADS 3 Lesions: Role of Prostate MRI Texture Analysis in the Identification of Prostate Cancer

2021

Abstract Purpose To determine the diagnostic performance of texture analysis of prostate MRI for the diagnosis of prostate cancer among Prostate Imaging Reporting and Data System (PI-RADS) 3 lesions. Materials and Methods Forty-three patients with at least 1 PI-RADS 3 lesion on prostate MRI performed between June 2016 and January 2019 were retrospectively included. Reference standard was pathological analysis of radical prostatectomy specimens or MRI-targeted biopsies. Texture analysis extraction of target lesions was performed on axial T2-weighted images and apparent diffusion coefficient (ADC) maps using a radiomic software. Lesions were categorized as prostate cancer (Gleason score [GS] …

Malemedicine.medical_specialtymedicine.medical_treatment030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancer0302 clinical medicineProstatemedicineHumansEffective diffusion coefficientRadiology Nuclear Medicine and imagingStatistical analysisPI-RADSRetrospective StudiesProstate cancerbusiness.industryProstatectomyProstatic NeoplasmsLinear discriminant analysismedicine.diseaseMagnetic Resonance ImagingConfidence intervalPI-RADSmedicine.anatomical_structure030220 oncology & carcinogenesisRadiologyNeoplasm GradingSettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessMRICurrent Problems in Diagnostic Radiology
researchProduct

Prediction by quantitative histology of pathological stage in prostate cancer.

2005

To find a predictor of extraprostatic extension in clinically localized prostate cancer (PCa), pre-operative ultrasound-guided prostate needle biopsies and clinico-pathological data were reviewed.One hundred and eighty-three consecutive patients who underwent radical retropubic prostatectomy for clinical T1-T2 PCa and serum PSA10 ng/ml were reviewed. Pre-operative biopsy was performed according to an extended protocol and whole-mount prostatectomy specimens were processed. The following biopsy variables were categorized to this analysis: Gleason score (or =6,6), TPC (or =20%;20%), GPC (or =50%;50%), cancer-positive cores (or =2;2), cancer-positive cores in both lateral portions (yes; no), P…

Malemedicine.medical_specialtymedicine.medical_treatmentBiopsyUrologyurologic and male genital diseasesLogistic regressionSensitivity and SpecificityProstate cancerProstatePredictive Value of TestsBiopsymedicineOdds RatioHumansStage (cooking)AgedNeoplasm Stagingmedicine.diagnostic_testbusiness.industryProstatic NeoplasmsGeneral MedicineOdds ratioMiddle AgedProstate-Specific Antigenmedicine.diseaseSurgerymedicine.anatomical_structureLogistic ModelsOncologyROC CurveMultivariate AnalysisSurgeryPositive Surgical MarginbusinessRadical retropubic prostatectomyEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

Is high dose rate brachytherapy reliable and effective treatment for prostate cancer patients? A review of the literature.

2014

The intrinsic physical and radiobiological characteristics of High Dose Rate Brachytherapy (HDR-BT) are well suited to the treatment of prostate cancer. HDR-BT was initially used as a boost to external beam brachytherapy, but has subsequently been employed as the sole treatment, which is termed HDR monotherapy. This review summarizes the clinical outcomes and toxicity results of the principal studies and discusses the radiobiological basis supporting its use.

Malemedicine.medical_specialtymedicine.medical_treatmentBrachytherapyBrachytherapyProstate cancermedicineEffective treatmentHumansMedical physicsDose FractionationSalvage brachytherapySalvage TherapyProstate cancerbusiness.industryRadiobiologyProstatic NeoplasmsRadiotherapy DosageHDR-BTHematologymedicine.diseaseBrachytherapy boost; HDR-BT; High-dose rate brachytherapy; Prostate cancer; Radiobiology; Salvage brachytherapy; Dose Fractionation; Humans; Male; Prostatic Neoplasms; Salvage Therapy; Treatment Outcome; Brachytherapy; Radiotherapy Dosage; Hematology; Oncology; Geriatrics and GerontologyHigh-Dose Rate BrachytherapyBrachytherapy boostTreatment OutcomeOncologyRadiologyDose Fractionation RadiationGeriatrics and GerontologybusinessHigh-dose rate brachytherapySalvage brachytherapyCritical reviews in oncology/hematology
researchProduct

Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored Treatment

2019

Background: Active surveillance (AS) has been increasingly proposed as the preferential initial management strategy for low-risk prostate cancer (PC), while in high-risk PC the indication for surgery has widened. Objective: To evaluate the development of risk group distribution of patients undergoing radical prostatectomy (RP). Design, setting, and participants: Retrospective database review of combined RP databases (2000-2015) of four large European centers (Créteil, Paris; San Rafaele, Milan; Martini Klinik, Hamburg; NKI, AvL, Amsterdam). Outcome measurements and statistical analysis: Clinical and pathological characteristics per year of surgery. Eligibility for AS was defined according …

Malemedicine.medical_specialtymedicine.medical_treatmentUrology030232 urology & nephrologyRisk classificationDiseaseActive surveillanceRisk AssessmentTreatment trend03 medical and health sciencesProstate cancer0302 clinical medicineRisk groupsInternal medicineHumansMedicineDistribution (pharmacology)Watchful WaitingPathologicalRetrospective StudiesProstatectomyProstate cancerbusiness.industryProstatectomyProstatic NeoplasmsCancerProstate-Specific Antigenmedicine.diseaseTailored treatmentRadical prostatectomySurgeryEurope030220 oncology & carcinogenesisNeoplasm Gradingbusiness
researchProduct